Navigation Links
Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
Date:10/15/2007

Of 13 studies analyzed, only Bifantis used appropriate study design to

demonstrate efficacy compared with placebo

PHILADELPHIA, Oct. 15 /PRNewswire/ -- A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis(R), Bifidobacterium infantis 35624, the sole ingredient in Align(R) (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Researchers at the University of Michigan conducted the review to evaluate the safety, efficacy and tolerability of probiotics for IBS in randomized controlled trials and found that, with the exception of the Bifidobacterium infantis 35624 studies, most were not designed in a way that made the data possible to validate. The review data were presented this week at the annual American College of Gastroenterology (ACG) conference taking place in Philadelphia, PA.

"There is growing interest in medical and patient communities about the use of probiotics in IBS and lots of data has been published about this topic, but it's helpful to know the quality of that data before making a treatment decision," said Darren Brenner, MD, lead investigator on this project. "Our analysis showed that only this particular strain of probiotic, Bifidobacterium infantis 35624, has valid data for successfully treating IBS symptoms. At this point, we just don't have enough valid data to determine if other probiotics are effective for IBS."

The Study

The goal of this systematic review of randomized controlled trials was to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Criteria for the study included randomized controlled trials testing adults with IBS symptoms using single or combination probiotics versus placebo for IBS symptoms and frequency of adverse events.

Of the 13 trials that met selection criteria, 11 demonstrated sub-optimal study design with inadequate blinding, inadequate trial length, inadequate sample size and lack of proper analysis. Only three studies provided quantifiable data about tolerability and adverse events, and the only probiotic to demonstrate significant improvement in IBS symptoms in appropriately designed studies was Bifidobacterium infantis 35624.

Bifidobacterium infantis 35624 showed significant improvement in the composite score of abdominal pain/discomfort, bloating/distention and bowel movement difficulty compared with placebo. A subsequent study showed that Bifidobacterium infantis 35624 demonstrated superior efficacy to the placebo for the primary outcome measure of abdominal pain/discomfort as well as for secondary measures including bloating/distention, incomplete evacuation, straining and passage of gas.

"From our discovery of the bacterium to the description of its genome and biological properties and, finally, to the clinical studies that have made this available to consumers in Align, our primary goal has been to provide accurate information on the benefits of Bifantis," said Eamonn Quigley, MD FACG and professor of Medicine and Human Physiology and Head of the Medical School, National University of Ireland (NUI).

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland. Please visit http://www.alimentaryhealth.ie for more information.

About APC

The Alimentary Pharmabiotic Centre (APC) is a Science Foundation Ireland (SFI) funded research centre headquartered in University College Cork (UCC), with scientists and clinicians also based in Teagasc Moorepark, Cork University Hospital and Alimentary Health Ltd. The APC is investigating mechanisms by which intestinal bacteria influence health and disease and is developing new therapies for lifelong debilitating gastrointestinal diseases such as gastroenteritis, ulcerative colitis and Crohn's disease. For information please visit http://apc.ucc.ie/.

About Align

Align is a daily probiotic supplement that helps build and maintain a strong and healthy digestive system.* Align works by providing a natural defense against episodic digestive upsets such as constipation, diarrhea, abdominal discomfort, urgency, gas and bloating. Align is the only probiotic supplement containing Bifantis (Bifidobacterium infantis 35624). Please visit AlignGI.com for more information.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contacts:

Bob Mathias Barry Kiely Shirley Johnson

Alimentary Health Alimentary Health Manning, Selvage & Lee

Phone 1 480 248 7278 +353 21 429 9104 (212) 468-3292

Email bmathias@ahealth.ie bkiely@ahealth.ie shirley.johnson@mslpr.com


'/>"/>
SOURCE Alimentary Health
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
3. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
4. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
5. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
6. Salix Pharmaceuticals Previews Digestive Disease Week 2007
7. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
8. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
9. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
10. Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results
11. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017   Divoti USA ... Alert Jewelry up to the standard of the latest FDA requirements, ... June 2017). Anyone in need of Medical ID jewelry ... Medical Alert Jewelry are engraved in terms of the ... Divoti ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):